Retro Biosciences raises the dose in its Alzheimer's trial

Sam Altman put $180 million into a company betting it can treat aging itself, not just its symptoms. That company, Retro Biosciences, built a drug called RTR242. It's meant to restore a cell's natural cleanup system, the process that fades as we age. Business Insider reports that early tests in healthy volunteers came back underwhelming at the original dose. So Retro is trying a stronger dose, adding two more groups to its trial in Australia.

Autophagy is the biology term for this cleanup process. Cells act like tiny recycling centers, breaking down and reusing their own damaged parts. That process slows as people age, and a lot of what looks like brain aging may trace back to it. RTR242 is designed to rev the process back up. The current trial only checks safety in healthy people, not whether the drug actually helps anyone with Alzheimer's or Parkinson's. Needing stronger doses just to see an effect is a normal part of early drug testing. It's also a reminder: Retro has years of testing left. Nobody yet knows if this works in sick patients, let alone reverses anything.

Keep reading — what to watch

Will a higher dose actually show a clearer effect, or just more side effects? That's the real question Retro's expanded trial is built to answer. The company hasn't disclosed what the original lower-dose results looked like. Outsiders are relying on reporting, not Retro's own data, to call it underwhelming. If the higher doses work and stay safe, Retro can move toward testing actual patients. That's the step that would finally show whether this approach helps anyone. If not, one of Sam Altman's biggest side bets goes back to the drawing board.